Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Work In Process (2023 - 2025)

Historic Work In Process for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Q3 2025 value amounting to $387000.0.

  • Rhythm Pharmaceuticals' Work In Process fell 5392.86% to $387000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $387000.0, marking a year-over-year decrease of 5392.86%. This contributed to the annual value of $1.2 million for FY2024, which is 1322.46% up from last year.
  • Rhythm Pharmaceuticals' Work In Process amounted to $387000.0 in Q3 2025, which was down 5392.86% from $767000.0 recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Work In Process ranged from a high of $3.5 million in Q3 2023 and a low of $387000.0 during Q3 2025
  • For the 3-year period, Rhythm Pharmaceuticals' Work In Process averaged around $1.7 million, with its median value being $1.5 million (2024).
  • Examining YoY changes over the last 5 years, Rhythm Pharmaceuticals' Work In Process showed a top increase of 1322.46% in 2024 and a maximum decrease of 7598.63% in 2024.
  • Rhythm Pharmaceuticals' Work In Process (Quarter) stood at $1.1 million in 2023, then rose by 13.22% to $1.2 million in 2024, then crashed by 69.04% to $387000.0 in 2025.
  • Its last three reported values are $387000.0 in Q3 2025, $767000.0 for Q2 2025, and $1.7 million during Q1 2025.